Context
What do CBD users actually report?
TL;DR — What the Evidence Shows
Surveys show many CBD users report pain relief. Clinical trials show no benefit over placebo for arthritis.
Both of these are true. This page explains why they may not contradict each other.
What do surveys find?
Several large surveys have asked CBD users about their experience. These surveys do not include a control group, so they cannot tell us whether CBD caused the improvements people report. They tell us what people say happened.
Arthritis Foundation Survey (2019)
More than 2,600 arthritis patients responded. The majority had been living with osteoarthritis (52% of respondents) or rheumatoid arthritis (45%) for 10 or more years.
- 29 out of 100 respondents reported currently using CBD
- About 3 out of 4 current users called it "effective" or "very effective"
- 94 out of 100 users said pain relief was the primary reason for use
- 71 out of 100 reported improvement in sleep
- 67 out of 100 reported improvement in physical function
(Arthritis Foundation 2019) Self-selected convenience sample.
Frane et al. (2022)
428 participants recruited through social media and Arthritis Foundation newsletters.
- 83 out of 100 reported pain improvement
- Users reported an average 44% reduction in pain (self-reported, uncontrolled)
- About 61 out of 100 reported reducing or stopping other medications
National polling data
- Gallup (2019): 14 out of 100 US adults reported currently using CBD (n=2,543)
- SingleCare (2020): 33 out of 100 Americans had tried CBD; 60%+ of CBD users across all age groups used it for pain; 32 out of 100 who tried it said it did not work
- Consumer Reports (2019): An estimated 64 million Americans had tried CBD; 20 out of 100 CBD users reported using it for arthritis
(Gallup 2019) SingleCare, April 2020; Consumer Reports, 2019.
What do clinical trials find?
Clinical trials use a placebo comparison. Participants do not know whether they receive CBD or an inactive substance. This design tests whether CBD provides benefit beyond what people experience from expecting to get better.
Three osteoarthritis-specific trials: all negative
Three randomized, double-blind, placebo-controlled trials tested CBD specifically for osteoarthritis pain (Vela 2022 (Vela 2022), n=136; Bialas 2023 (Bialas 2023), n=86; CANOA 2025 (Mojoli 2025)). None found a statistically or clinically significant benefit over placebo.
In the Vela trial, the difference between CBD and placebo on a 100-point pain scale was 0.23 points. That is effectively zero.
Broader CBD pain trial review
Moore et al. (2024) reviewed 16 randomized controlled trials testing CBD for pain. 15 out of 16 found no significant benefit over placebo. (Moore 2024)
Why might surveys and trials disagree?
This gap between what people report and what controlled trials find is well-documented in pain research. Several factors can explain it:
Placebo response
In pain trials, up to 30 out of 100 people improve on placebo alone. A 2022 meta-analysis of cannabinoid pain trials found a "significant pain reduction in response to placebo" and that placebo "contributes significantly to pain reduction seen in cannabinoid clinical trials" (Gedin 2022).
Expectation effects
Believing a treatment will help can change how the brain processes pain. In one study, participants who were told they received CBD (regardless of whether they actually did) showed changes in pain response (De Vita 2022). Media coverage of cannabis studies is overwhelmingly positive regardless of actual study outcomes, which may increase expectations.
Regression to the mean
People tend to try new treatments when their pain is at its worst. Pain naturally fluctuates. Even without any treatment, many people would have improved. Without a placebo group, surveys cannot separate natural improvement from treatment effect.
Uncontrolled variables
Survey respondents may also be exercising more, losing weight, using other treatments, or making lifestyle changes at the same time they start CBD. Surveys cannot isolate the effect of CBD from everything else happening in a person's life.
Publication and recall bias
People who felt benefit are more likely to respond to a survey about CBD. People who tried it once and stopped are less likely to participate. On Reddit, about 90 out of 100 posts about CBD claim it works (Tran 2020). In controlled trials, the benefit is not distinguishable from placebo.
Does this mean CBD users are wrong?
No. Subjective benefit is real. A person who feels less pain feels less pain. That experience is not imaginary.
But subjective benefit alone cannot establish that CBD caused the improvement. That is what controlled trials test. They compare people who get CBD to people who get a look-alike placebo under identical conditions. When both groups improve by the same amount, the improvement is real for everyone, but CBD was not the cause.
The three osteoarthritis-specific trials and 15 of 16 broader CBD pain trials have not found a CBD-specific effect. This does not prove that CBD cannot help anyone. It means the current evidence cannot confirm that it does.
What do we not know?
- Whether specific formulations matter. The trials tested specific products. Whether different formulations (full-spectrum vs. isolate, different delivery methods) might produce different results is not established.
- Whether certain doses have not been tested. Osteoarthritis trials tested doses from 20 to 600 mg per day. No study designed to determine the most effective dose has been conducted for arthritis.
- Whether some patient groups might respond differently. No trial has identified a subgroup of patients who benefit from CBD. The trials so far have been too small to detect subgroup effects.
- Why the gap is so large for CBD specifically. The Gedin et al. meta-analysis (Gedin 2022) found that media attention about cannabis therapies was linked to higher placebo response rates. Whether CBD's unique cultural visibility inflates expectations more than other supplements is unknown.
CBD interacts with many common medications
- Blood thinners (warfarin): CBD can increase bleeding risk by raising INR levels
- Statins, blood pressure medications, and immunosuppressants may also be affected
- CBD inhibits the same liver enzymes that process many prescription drugs
Based on cited sources. This is not personalized medical advice — discuss with your healthcare provider.
Full drug interaction guide, medication checker, and pharmacist discussion checklist.
Key sources cited on this page
Page last reviewed: March 2026 · Authored by Claude (Anthropic AI) · Research methodology